Microbial growth growing inside a petri dish Credit: File In biotech, discovering something that can change medicine might just be the easy part. Getting it from a laboratory bench into a hospital, or pathology clinic can actually present as many, if not more challenges than uncovering the discovery itself. Imagine a hypothetical ASX junior we’ll call XYZ Bio. Its scientists have discovered a molecule they believe could treat an aggressive cancer. Laboratory results loo

Melbourne-based biotech Amplia Therapeutics is collaborating with Eli Lilly & Company to trial its narmafotinib FAK blocker drug for non-small cell lung cancer. Melbourne-based ASX listed biotech Amplia Therapeutics (ASX: ATX) has secured a major collaboration with pharmaceutical goliath Eli Lilly & Company to evaluate a new combination therapy aimed at tackling non-small cell lung cancer (NSCLC). The two companies have signed a Clinical Trial Collaboration and Supply A

Amplia Therapeutics’ says fresh preclinical research data has strengthened the case for its drug candidate narmafotinib against pancreatic cancer cells, pictured. Amplia Therapeutics (ASX: ATX) has received encouraging lab results which highlighted the use of its lead drug narmafotinib, saying it can attack several of the nastier features that make the cancer so hard to treat. The research, led by Professor Paul Timpson and colleagues at Sydney’s Garvan Institute of Med

Amplia Therapeutics incoming chairman Ms Jane Bell AM Amplia Therapeutics (ASX: ATX) has refreshed its board, handing the chairman's role to experienced life sciences director Jane Bell AM as the Melbourne-based drug developer looks to convert encouraging clinical momentum into regulatory and commercial success. The company has framed the transition as part of a planned board renewal and succession process, timed to align with a genuine inflection point for its lead dru

Amplia Therapeutics’ business development team recently attended the prestigious 2026 American Society of Clinical Oncology conference in Chicago, USA. While many cancer companies spend billions trying to make stronger chemotherapies, Melbourne-based Amplia Therapeutics (ASX: ATX) is taking a different path, developing a “shield-breaking” treatment that makes other multi-billion-dollar drugs work better. Following the world's premier American Society of Clinical Oncolog

Amplea Therapeutics managing director and chief executive officer Dr Chris Burns. For everyday punters looking at medical technology companies, the best opportunities often come from identifying a drug that makes other multi-billion-dollar treatments work better. That is the main idea behind Melbourne-based medical company Amplia Therapeutics (ASX: ATX). While most cancer companies spend billions trying to make stronger, more toxic chemotherapies, Amplia is taking a dif

Amplia Therapeutics and the Australia New Zealand Gynaecological Group have announced a new ovarian cancer study. ASX-listed Amplia Therapeutics (ASX: ATX) is aggressively broadening its clinical reach, unveiling a major new collaboration to throw its lead drug candidate, narmafotinib, into the ring against ovarian cancer. The company has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study to evaluate its pro

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics, after the company unveiled results for a potential golden bullet for pancreatic cancer.